RU2012108173A - Терапевтические арил-амидо-арильные соединения и их применение - Google Patents
Терапевтические арил-амидо-арильные соединения и их применение Download PDFInfo
- Publication number
- RU2012108173A RU2012108173A RU2012108173/04A RU2012108173A RU2012108173A RU 2012108173 A RU2012108173 A RU 2012108173A RU 2012108173/04 A RU2012108173/04 A RU 2012108173/04A RU 2012108173 A RU2012108173 A RU 2012108173A RU 2012108173 A RU2012108173 A RU 2012108173A
- Authority
- RU
- Russia
- Prior art keywords
- aaa
- independently represents
- olr
- compound according
- saturated aliphatic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 31
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 8
- 150000004677 hydrates Chemical class 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000012453 solvate Substances 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- -1 pyrrolidino, piperidino Chemical group 0.000 claims abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 15
- 208000010877 cognitive disease Diseases 0.000 claims 8
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 206010039966 Senile dementia Diseases 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims 3
- ZKPSTNOENWFZGP-UHFFFAOYSA-N 4-[(3,5-dichloro-4-ethoxybenzoyl)amino]benzoic acid Chemical compound C1=C(Cl)C(OCC)=C(Cl)C=C1C(=O)NC1=CC=C(C(O)=O)C=C1 ZKPSTNOENWFZGP-UHFFFAOYSA-N 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- GHEJAAXZTTXGRW-UHFFFAOYSA-N 4-[(3,5-dichloro-4-methoxybenzoyl)amino]benzoic acid Chemical compound C1=C(Cl)C(OC)=C(Cl)C=C1C(=O)NC1=CC=C(C(O)=O)C=C1 GHEJAAXZTTXGRW-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- NYELPSPJJUSESF-UHFFFAOYSA-N CC(C)Oc(cc(cc1Cl)C(Nc2ccc(C(O)=O)c(C)c2)=O)c1OC Chemical compound CC(C)Oc(cc(cc1Cl)C(Nc2ccc(C(O)=O)c(C)c2)=O)c1OC NYELPSPJJUSESF-UHFFFAOYSA-N 0.000 description 1
- INWHHEOTPXALAJ-UHFFFAOYSA-N CC(C)Oc1cc(C(Nc(cc2)cc(O)c2C(O)=O)=O)cc(OC(C)C)c1Br Chemical compound CC(C)Oc1cc(C(Nc(cc2)cc(O)c2C(O)=O)=O)cc(OC(C)C)c1Br INWHHEOTPXALAJ-UHFFFAOYSA-N 0.000 description 1
- PDVCKFFYLUHHTF-UHFFFAOYSA-N CC(C)Oc1cc(C(Nc(cc2)ccc2C(O)=O)=O)cc(Cl)c1OC Chemical compound CC(C)Oc1cc(C(Nc(cc2)ccc2C(O)=O)=O)cc(Cl)c1OC PDVCKFFYLUHHTF-UHFFFAOYSA-N 0.000 description 1
- WRVMJOWZMVWZGC-UHFFFAOYSA-N CCC(CC)Oc(cc(cc1Cl)C(Nc(cc2)ccc2C(O)=O)=O)c1OC Chemical compound CCC(CC)Oc(cc(cc1Cl)C(Nc(cc2)ccc2C(O)=O)=O)c1OC WRVMJOWZMVWZGC-UHFFFAOYSA-N 0.000 description 1
- 0 CCOc(c(Cl)cc(C(Nc1ccc(C(O)=O)c(*)c1)=O)c1)c1OC(C)C Chemical compound CCOc(c(Cl)cc(C(Nc1ccc(C(O)=O)c(*)c1)=O)c1)c1OC(C)C 0.000 description 1
- ZWBXDTPGJLLDCM-UHFFFAOYSA-N CCOc(c(Cl)cc(C(Nc1ccc(C(O)=O)c(C)c1)=O)c1)c1OC(C)C Chemical compound CCOc(c(Cl)cc(C(Nc1ccc(C(O)=O)c(C)c1)=O)c1)c1OC(C)C ZWBXDTPGJLLDCM-UHFFFAOYSA-N 0.000 description 1
- IIHVDCZTZOBXRM-UHFFFAOYSA-N COC(c(cc1)ccc1NC(c(cc1Cl)cc(Cl)c1OC1CCCC1)=O)=O Chemical compound COC(c(cc1)ccc1NC(c(cc1Cl)cc(Cl)c1OC1CCCC1)=O)=O IIHVDCZTZOBXRM-UHFFFAOYSA-N 0.000 description 1
- ROFQZPNVSNGRPP-UHFFFAOYSA-N OC(c(cc1)ccc1NC(c(cc1Cl)cc(Cl)c1OCC1CC1)=O)=O Chemical compound OC(c(cc1)ccc1NC(c(cc1Cl)cc(Cl)c1OCC1CC1)=O)=O ROFQZPNVSNGRPP-UHFFFAOYSA-N 0.000 description 1
- ISSWNTGWCNUBMI-UHFFFAOYSA-N OC(c(cc1)ccc1NC(c(cc1Cl)cc(Cl)c1OCc1ccccc1)=O)=O Chemical compound OC(c(cc1)ccc1NC(c(cc1Cl)cc(Cl)c1OCc1ccccc1)=O)=O ISSWNTGWCNUBMI-UHFFFAOYSA-N 0.000 description 1
- ULVXRZNMPNRMBL-UHFFFAOYSA-N OC(c(cc1)ccc1NC(c(cc1Cl)cc(OC2CCCC2)c1OC1CCCC1)=O)=O Chemical compound OC(c(cc1)ccc1NC(c(cc1Cl)cc(OC2CCCC2)c1OC1CCCC1)=O)=O ULVXRZNMPNRMBL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0915196.0A GB0915196D0 (en) | 2009-09-01 | 2009-09-01 | Therapeutic compounds and their use |
| GB0915196.0 | 2009-09-01 | ||
| PCT/GB2010/001650 WO2011027106A1 (en) | 2009-09-01 | 2010-09-01 | Therapeutic aryl-am i do-aryl compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012108173A true RU2012108173A (ru) | 2013-10-10 |
Family
ID=41202973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012108173/04A RU2012108173A (ru) | 2009-09-01 | 2010-09-01 | Терапевтические арил-амидо-арильные соединения и их применение |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120149737A1 (https=) |
| EP (1) | EP2473479A1 (https=) |
| JP (1) | JP5778675B2 (https=) |
| CN (1) | CN102639487A (https=) |
| AU (1) | AU2010291056B2 (https=) |
| BR (1) | BR112012004173A2 (https=) |
| CA (1) | CA2771097C (https=) |
| GB (1) | GB0915196D0 (https=) |
| IL (1) | IL218137A (https=) |
| MX (1) | MX2012002481A (https=) |
| NZ (1) | NZ598331A (https=) |
| RU (1) | RU2012108173A (https=) |
| SG (1) | SG178480A1 (https=) |
| WO (1) | WO2011027106A1 (https=) |
| ZA (1) | ZA201201287B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0915196D0 (en) | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| WO2012125749A2 (en) * | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
| CN102727475B (zh) * | 2012-06-14 | 2014-05-07 | 合肥博太医药生物技术发展有限公司 | 视黄酸及其衍生物在制备防治老年痴呆药物中的应用 |
| JP6596090B2 (ja) * | 2014-12-17 | 2019-10-23 | キングス カレッジ ロンドン | レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物 |
| EP3267969A1 (en) * | 2015-03-09 | 2018-01-17 | King's College London | Combination therapy with rar alpha agonists for enhancing th1 response |
| WO2017066428A1 (en) | 2015-10-13 | 2017-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Brd4-kinase inhibitors as cancer therapeutics |
| WO2017174999A1 (en) * | 2016-04-07 | 2017-10-12 | High Force Research Limited | Synthetic retinoids for use in rar mediated conditions |
| CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
| GB201900687D0 (en) | 2019-01-17 | 2019-03-06 | King S College London | Immunotherapeutic methods and compositions |
| AU2019400930A1 (en) | 2018-12-19 | 2021-07-01 | King's College London | Immunotherapeutic methods and compositions |
| CA3128032A1 (en) | 2019-01-29 | 2020-08-06 | The Johns Hopkins University | Small molecule neutral sphingomyelinase 2 (nsmase2) inhibitors |
| WO2020263960A1 (en) * | 2019-06-28 | 2020-12-30 | Carl Wagner | Compositions comprising a retinoid x receptor (rxr) agonist, a retinoic acid receptor (rar) agonist, or a dual rxr/rar agonist |
| JP2026500298A (ja) | 2022-12-15 | 2026-01-06 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤として有用である新規な二環式カルボキサミド化合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2260118C2 (de) | 1972-12-08 | 1982-06-03 | Bayer Ag, 5090 Leverkusen | Penicilline sowie ihre Verwendung als Arzneimittel |
| DE3580134D1 (de) | 1984-07-07 | 1990-11-22 | Shudo Koichi Prof Dr Chem | Benzoesaeurederivate. |
| JPS61233678A (ja) | 1985-04-09 | 1986-10-17 | Maruko Seiyaku Kk | ベンジルピペラジン誘導体 |
| JPS62215581A (ja) | 1986-03-18 | 1987-09-22 | Koichi Shiyudo | フラボンカルボン酸誘導体 |
| US4808631A (en) | 1986-11-07 | 1989-02-28 | Hoffmann-La Roche Inc. | Aromatic acid derivatives |
| US4992468A (en) | 1989-07-26 | 1991-02-12 | Allergan, Inc. | Phenylethenyl compounds having retinoid-like activity |
| ZA911101B (en) * | 1990-02-14 | 1991-11-27 | Chugai Pharmaceutical Co Ltd | Inhibition of modified ldl products |
| FR2663850B1 (fr) | 1990-07-02 | 1994-01-14 | Gird Galderma | Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol. |
| EP0619116A3 (en) | 1993-04-05 | 1994-11-23 | Hoechst Japan | Use of synthetic retinoids for osteopathy. |
| US5648385A (en) | 1994-01-03 | 1997-07-15 | Bristol-Myers Squibb Co. | Retinoid-like compounds |
| US5849735A (en) | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5559248A (en) | 1995-04-05 | 1996-09-24 | Bristol-Myers Squibb Co. | Retinoid-like heterocycles |
| ES2180751T3 (es) | 1995-04-10 | 2003-02-16 | Taiho Pharmaceutical Co Ltd | Inhibidor de metastasis de cancer. |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| FR2739777B1 (fr) | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| US5663357A (en) * | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
| HUP0102470A3 (en) | 1998-07-01 | 2002-05-28 | Takeda Chemical Industries Ltd | 1,3-azole derivatives as retinoid-associated receptor regulators and their use |
| US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| PL198852B1 (pl) | 1998-10-22 | 2008-07-31 | Neurosearch As | Podstawione pochodne fenylu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie |
| TW400614B (en) | 1998-11-06 | 2000-08-01 | United Microelectronics Corp | The manufacture method of Shallow Trench Isolation(STI) |
| US6897304B2 (en) | 2000-09-22 | 2005-05-24 | Zenyaku Kogyo Kabushiki Kaisha | Cephem compounds and ESBL-detecting reagents containing the same |
| CA2432825A1 (en) | 2000-12-15 | 2002-06-20 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
| GB0103998D0 (en) | 2001-02-19 | 2001-04-04 | King S College London | Method |
| US7105566B2 (en) * | 2002-10-22 | 2006-09-12 | Allergan, Inc. | Methods of treatment during vascular procedures |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| KR100921173B1 (ko) * | 2007-11-14 | 2009-10-13 | (주)아모레퍼시픽 | 피부 내에서 히알루론산 생합성을 촉진시키는3,4,5-트리메톡시벤즈 아미드 유도체 화합물, 그 제조방법및 이를 함유하는 화장료 조성물 |
| EP2415755A4 (en) | 2009-03-31 | 2012-09-19 | Renascience Co Ltd | INHIBITOR AGENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1 |
| GB0915196D0 (en) | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| WO2012058378A1 (en) | 2010-10-29 | 2012-05-03 | Romark Laboratories L.C. | Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses |
-
2009
- 2009-09-01 GB GBGB0915196.0A patent/GB0915196D0/en not_active Ceased
-
2010
- 2010-09-01 AU AU2010291056A patent/AU2010291056B2/en not_active Ceased
- 2010-09-01 CA CA2771097A patent/CA2771097C/en not_active Expired - Fee Related
- 2010-09-01 EP EP10752907A patent/EP2473479A1/en not_active Withdrawn
- 2010-09-01 JP JP2012526118A patent/JP5778675B2/ja not_active Expired - Fee Related
- 2010-09-01 NZ NZ598331A patent/NZ598331A/xx not_active IP Right Cessation
- 2010-09-01 RU RU2012108173/04A patent/RU2012108173A/ru not_active Application Discontinuation
- 2010-09-01 MX MX2012002481A patent/MX2012002481A/es not_active Application Discontinuation
- 2010-09-01 WO PCT/GB2010/001650 patent/WO2011027106A1/en not_active Ceased
- 2010-09-01 US US13/391,207 patent/US20120149737A1/en not_active Abandoned
- 2010-09-01 CN CN2010800493386A patent/CN102639487A/zh active Pending
- 2010-09-01 SG SG2012011193A patent/SG178480A1/en unknown
- 2010-09-01 BR BR112012004173A patent/BR112012004173A2/pt not_active IP Right Cessation
-
2012
- 2012-02-16 IL IL218137A patent/IL218137A/en active IP Right Grant
- 2012-02-21 ZA ZA2012/01287A patent/ZA201201287B/en unknown
-
2015
- 2015-10-09 US US14/879,340 patent/US9447028B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010291056A1 (en) | 2012-03-15 |
| IL218137A (en) | 2016-06-30 |
| US20120149737A1 (en) | 2012-06-14 |
| GB0915196D0 (en) | 2009-10-07 |
| ZA201201287B (en) | 2013-05-29 |
| CA2771097C (en) | 2019-01-15 |
| CA2771097A1 (en) | 2011-03-10 |
| EP2473479A1 (en) | 2012-07-11 |
| CN102639487A (zh) | 2012-08-15 |
| SG178480A1 (en) | 2012-04-27 |
| WO2011027106A1 (en) | 2011-03-10 |
| MX2012002481A (es) | 2012-03-26 |
| JP2013503819A (ja) | 2013-02-04 |
| JP5778675B2 (ja) | 2015-09-16 |
| US9447028B2 (en) | 2016-09-20 |
| AU2010291056B2 (en) | 2016-01-28 |
| IL218137A0 (en) | 2012-06-28 |
| NZ598331A (en) | 2013-10-25 |
| BR112012004173A2 (pt) | 2017-05-30 |
| US20160039747A1 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012108173A (ru) | Терапевтические арил-амидо-арильные соединения и их применение | |
| RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| JP2002541245A5 (https=) | ||
| JP2023521116A5 (https=) | ||
| RU2351592C2 (ru) | Производные тетрагидрохинолина и фармацевтическая композиция на их основе для лечения и профилактики вич-инфекции | |
| RU2015106605A (ru) | Соединения замещенных пиразолонов и способы использования | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| RU2005117341A (ru) | Пиримидиновые соединения, обладающие антипролиферативной активностью (ii) | |
| RU2003120798A (ru) | Новые производные n-(фенилсульфонил) глицина и их применение в терапии | |
| RU2001130140A (ru) | Производные адамантана | |
| RU2012104244A (ru) | Аналоги tofa, применимые при лечении дерматологических расстройств или состояний | |
| JP2006503866A5 (https=) | ||
| RU2010117225A (ru) | Аналоги хинолона и относящиеся к ним способы | |
| JP2005519908A5 (https=) | ||
| RU2002104935A (ru) | ПРОИЗВОДНЫЕ 8-ФЕНИЛ-6,9-ДИГИДРО[1,2,4]ТРИАЗОЛО[3,4-i]ПУРИН-5-ОНА | |
| JP2005508336A5 (https=) | ||
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| RU2007109870A (ru) | 2,4-ди(аминофенил)пиримидины в качестве ингибиторов plk-киназ | |
| WO2006086705B1 (en) | Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists | |
| RU2005113153A (ru) | Новые пиримидинамидные производные и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150824 |